Bharat Biotech's Covaxin has shown 77.8 per cent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday. The Hyderabad-based COVID vaccine manufacturing company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend. Bharat Biotech's 'pre-submission' meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin. Watch the full video for more details.